CNS Disorders  >>  Lybalvi (olanzapine/samidorphan) 
Welcome,         Profile    Billing    Logout  

4 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lybalvi (olanzapine/samidorphan) / Alkermes
NCT03201757 / 2017-000918-36: Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831

Completed
3
524
Europe, US, RoW
ALKS 3831
Alkermes, Inc.
Schizophrenia, Schizophreniform Disorder, Bipolar I Disorder
09/23
09/23
NCT05303064: Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder

Recruiting
3
220
US, RoW
OLZ/SAM, ALKS 3831, LYBALVI, Olanzapine
Alkermes, Inc.
Schizophrenia, Bipolar I Disorder
09/26
09/26
NCT04987229: Long-term Safety Extension Study of OLZ/SAM in Pediatric Subjects

Enrolling by invitation
3
236
US, RoW
OLZ/SAM, ALKS 3831
Alkermes, Inc.
Bipolar I Disorder, Schizophrenia
09/27
09/27
NCT04987658: Phase 1 Study of OLZ/SAM in Pediatric Subjects With Bipolar I Disorder

Completed
1
7
US
OLZ/SAM, ALKS 3831
Alkermes, Inc.
Bipolar I Disorder
08/23
08/23

Download Options